Abstract: Disclosed is a method of treating a chronic tympanic perforation with a PCL patch tissue regeneration scaffold comprising preparing solution by adding polycaprolactone (PCL) and an acid to an organic solvent; preparing an electrospinning solution by adding a growth factor to the solution and stirring; collecting nanofibers arranged in a spindle shape on a collector by connecting the electrospinning solution prepared to a syringe pump and operating the electrospinning device; and administering the PCL patch tissue regeneration scaffold to a subject.

Abstract: A composition for preventing or treating hearing loss, containing a Vitis vinifera leaf extract as an active ingredient, is disclosed. A pharmaceutical composition for preventing or treating hearing loss, containing the extract (a Vitis vinifera leaf extract) as an active ingredient, protects auditory hair cells in the cochlea and spiral ganglion cells from damage caused by noise and the like and effectively reduces the hearing threshold measured in the auditory nerves, thereby being usable as an agent for preventing or treating hearing loss.

Abstract: The present invention relates to a pharmaceutical composition, containing sarpogrelate or a pharmaceutically acceptable salt thereof as an active ingredient, for preventing, alleviating, or treating sensorineural hearing loss. The sarporgrelate according to the present invention protects against hearing loss caused by noise through the suppression of auditory cell apoptosis and the expression increase of antioxidant enzyme in auditory cells, and thus can be advantageously used in the prevention and alleviation of sensorineural hearing loss.

Abstract: A composition containing a Vitis vinifera leaf extract as an active ingredient and its uses in preventing or treating tinnitus are disclosed. The composition may be a pharmaceutical composition or a food composition. The composition containing a Vitis vinifera leaf extract as an active ingredient is excellent in alleviating and improving tinnitus caused by noise and the like, and therefore is very useful as a composition for preventing or treating tinnitus.

Abstract: The present invention relates to a composition for preventing or treating hearing loss, containing an HMG-CoA reductase inhibitor and, more specifically, to a composition for preventing or treating diabetes-mediated hearing loss, containing, as an active ingredient(s), one or more types selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. A pharmaceutical composition containing an HMG-CoA reductase inhibitor, according to the present invention, inhibits auditory cell death caused by diabetes, and thus is very useful as an agent for preventing or treating diabetes-mediated sensorineural hearing loss.

Abstract: A pharmaceutical composition containing forskolin and retinoic acid as active ingredients which is suitable for preventing or treating sensorineural hearing loss is disclosed. A pharmaceutical composition containing forskolin and retinoic acid as active ingredients has an excellent effect of preventing, alleviating or treating hearing loss caused by ototoxic drugs during anticancer treatment, and thus is useful as a pharmaceutical composite preparation capable of reducing side effects of anticancer drugs and, additionally, as an agent for preventing or treating sensorineural hearing loss.

Abstract: A composition for preventing or treating hearing loss, containing a Vitis vinifera leaf extract as an active ingredient, is disclosed. A pharmaceutical composition for preventing or treating hearing loss, containing the extract (a Vitis vinifera leaf extract) as an active ingredient, protects auditory hair cells in the cochlea and spiral ganglion cells from damage caused by noise and the like and effectively reduces the hearing threshold measured in the auditory nerves, thereby being usable as an agent for preventing or treating hearing loss.

Abstract: Disclosed is a method of preparing PCL patch tissue regeneration scaffold comprising preparing solution by adding polycaprolactone (PCL) and an acid to an organic solvent; preparing an electrospinning solution by adding a growth factor to the solution and stirring; and collecting nanofibers arranged in a spindle shape on a collector by connecting the electrospinning solution prepared to a syringe pump and operating the electrospinning device.

Abstract: The present invention relates to a pharmaceutical composition, containing sarpogrelate or a pharmaceutically acceptable salt thereof as an active ingredient, for preventing, alleviating, or treating sensorineural hearing loss. The sarporgrelate according to the present invention protects against hearing loss caused by noise through the suppression of auditory cell apoptosis and the expression increase of antioxidant enzyme in auditory cells, and thus can be advantageously used in the prevention and alleviation of sensorineural hearing loss.

Abstract: The present invention relates to a composition for preventing or treating hearing loss, containing an HMG-CoA reductase inhibitor and, more specifically, to a composition for preventing or treating diabetes-mediated hearing loss, containing, as an active ingredient(s), one or more types selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. A pharmaceutical composition containing an HMG-CoA reductase inhibitor, according to the present invention, inhibits auditory cell death caused by diabetes, and thus is very useful as an agent for preventing or treating diabetes-mediated sensorineural hearing loss.

Abstract: The present invention provides a compound having an effect of preventing and/or treating the damage or degeneration of cochlear (and vestibular) mother cells and spiral ganglion neurons by downregulating a cysteinyl leukotriene receptor. Particularly, the present invention provides a composition for preventing or treating sensorineural hearing loss, containing a cysteinyl leukotriene receptor and a Ginkgo biloba extract as active ingredients, on the basis of the co-administration of a cysteinyl leukotriene receptor and a Ginkgo biloba extract having an excellent effect of protecting hearing.

Abstract: A pharmaceutical or health food includes rapamycin as an active ingredient, the pharmaceutical or health food being applied for prevention, improvement, and treatment of ototoxic hearing loss caused by an aminoglycoside-based antibiotic, sudden sensorineural hearing loss, and noise induced hearing loss. The pharmaceutical or health food is also applied to a pharmaceutical composite preparation of an aminoglycoside-based antibiotic and rapamycin, the pharmaceutical composite preparation reducing a side effect of the aminoglycoside-based antibiotic.

Abstract: The present invention is related to a pharmaceutical composition and health food for preventing or treating hearing loss, wherein the pharmaceutical composition and health food contain carbenoxolone or its pharmaceutically acceptable salts as an effective component. More particularly, a composition including carbenoxolone or its pharmaceutically acceptable salts as an effective component is provided as a pharmaceutical composition for preventing or treating ototoxic hearing loss due to the carbenoxolone or its pharmaceutically acceptable salts prevent damages on auditory cells from ototoxic drugs such as cisplatin anticancer drugs, and the composition may be used as a drug for treating noise-induced hearing loss and age-related hearing loss, as well as ototoxic hearing loss.

Abstract: The present invention provides a compound having an effect of preventing and/or treating the damage or degeneration of cochlear (and vestibular) mother cells and spiral ganglion neurons by downregulating a cysteinyl leukotriene receptor. Particularly, the present invention provides a composition for preventing or treating sensorineural hearing loss, containing a cysteinyl leukotriene receptor and a ginkgo biloba extract as active ingredients, on the basis of the co-administration of a cysteinyl leukotriene receptor and a ginkgo biloba extract having an excellent effect of protecting hearing.

Abstract: The present invention is related to a pharmaceutical composition and health food for preventing or treating hearing loss, wherein the pharmaceutical composition and health food contain carbenoxolone or its pharmaceutically acceptable salts as an effective component. More particularly, a composition including carbenoxolone or its pharmaceutically acceptable salts as an effective component is provided as a pharmaceutical composition for preventing or treating ototoxic hearing loss due to the carbenoxolone or its pharmaceutically acceptable salts prevent damages on auditory cells from ototoxic drugs such as cisplatin anticancer drugs, and the composition may be used as a drug for treating noise-induced hearing loss and age-related hearing loss, as well as ototoxic hearing loss.

Abstract: A pharmaceutical or health food includes rapamycin as an active ingredient, the pharmaceutical or health food being applied for prevention, improvement, and treatment of ototoxic hearing loss caused by an aminoglycoside-based antibiotic, sudden sensorineural hearing loss, and noise induced hearing loss. The pharmaceutical or health food is also applied to a pharmaceutical composite preparation of an aminoglycoside-based antibiotic and rapamycin, the pharmaceutical composite preparation reducing a side effect of the aminoglycoside-based antibiotic.